Modena, Italy: Patients with sleep disorders respond favorably to the co-administration of CBD and melatonin, according to data published in the Italian journal La Clinica Terapeutica.
A team of Italian researchers assessed the short-term administration of a sublingual compound consisting of 15mgs of melatonin and 2.5 mgs of plant-derived CBD in a cohort of middle-aged to older adults (ages 43 to 96) with a history of sleep disorders and anxiety. Study participants self-administered 20 drops of the compound prior to bedtime for a three-month period.
Researchers reported that CBD/melatonin co-administration was associated with reduced feelings of anxiety, pain, depression, panic, and paranoia, as well as with “good general health perceptions.”
They concluded, “These data suggest that the formula CBD-melatonin could be competitive with the classic hypnotic synthetic drugs; the antioxidant activity of melatonin offers a further benefit to the brain network, restoring the biological clock functions, while CBD, reducing chronic pain perception, helps to complete the neuromuscular relaxation and to relieve anxiety fulfilling a very balanced sensation of well-being during the sleep.”
Clinical trials have previously shown that the administration of either oral cannabinoid products or plant-derived cannabis extracts is associated with improvements in sleep in patients with insomnia. Observational studies also have shown that subjects who use herbal cannabis prior to bedtime report significant improvements in perceived insomnia levels and severity.
Full text of the study, “Insomnia treatment: A new multi-tasking natural compound based on melatonin and cannabis extracts,” appears in La Clinica Terapeutica.